Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of chronic obstructive pulmonary disease (COPD) (moderate-to-severe as classified by the Global Initiative for Chronic Obstructive Lung Disease \[GOLD\] Guidelines, 2007) and:~  1. Smoking history of at least 10 pack-years~ 2. Post-bronchodilator forced expiratory volume in 1 second (FEV1) ≤ 65% and ≥ 30% of the predicted normal value~ 3. Post-bronchodilator FEV1/FVC (force vital capacity) \< 70%~Exclusion Criteria:~* Patients who have had a COPD exacerbation requiring systemic glucocorticosteroid treatment or antibiotics and/or hospitalization in the 6 weeks prior to screening or during the run-in period~* Patients who have had a respiratory tract infection within 6 weeks prior to screening or during the run-in period~* Patients with a body mass index less than 15 or more than 40 kg/m\^2~* Patients with concomitant pulmonary disease~* Patients with a history of asthma~* Patients with diabetes Type I or uncontrolled diabetes Type II~* Any patient with lung cancer or a history of lung cancer~* Patients with a history of certain cardiovascular comorbid conditions~Other protocol-defined inclusion/exclusion criteria applied to the study.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Indacaterol 150 μg and tiotropium 18 μg (Type: EXPERIMENTAL): Patients inhaled indacaterol 150 μg and tiotropium 18 μg once daily in the morning between 8:00 AM and 11:00 AM for 12 weeks. Indacaterol was delivered blinded via a single dose dry powder inhaler (SDDPI). Tiotropium was delivered open-label via the manufacturer's proprietary inhalation device (HandiHaler®). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
- Tiotropium 18 μg (Type: ACTIVE_COMPARATOR): Patients inhaled placebo to indacaterol 150 μg and tiotropium 18 μg once daily in the morning between 8:00 AM and 11:00 AM for 12 weeks. Placebo to indacaterol was delivered blinded via a single dose dry powder inhaler (SDDPI). Tiotropium was delivered open-label via the manufacturer's proprietary inhalation device (HandiHaler®). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).